Patents by Inventor Julien Sage

Julien Sage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ABSCOPAL THERAPY FOR CANCER
    Publication number: 20240034788
    Abstract: Methods and compositions are provided for the treatment of cancer with a targeted therapy in combination with radiation. Administration of an effective dose or series of doses of a CD47 blocking agent, i.e. an agent that blocks the interaction between CD47 and SIRP?, is combined with radiation therapy to provide for an abscopal effect. In some embodiments the cancer is a metastatic cancer, or a cancer with a high likelihood of metastasis.
    Type: Application
    Filed: August 18, 2021
    Publication date: February 1, 2024
    Inventors: Julien Sage, Edward Graves, Yoko Nishiga
  • TARGETED THERAPY FOR SMALL CELL LUNG CANCER
    Publication number: 20210277115
    Abstract: Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRP?.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Inventors: Kipp Andrew Weiskopf, Julien Sage, Irving L. Weissman
  • Targeted therapy for small cell lung cancer
    Patent number: 11046763
    Abstract: Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRP?.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: June 29, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Kipp Andrew Weiskopf, Julien Sage, Irving L. Weissman
  • Targeted Therapy for Small Cell Lung Cancer
    Publication number: 20160333093
    Abstract: Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRP?.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Inventors: Kipp Andrew Weiskopf, Julien Sage, Irving L. Weissman